Corona Remedies share price rises ahead of Q2 results announcement

The stock was trading 0.62% higher at ₹1,411. 0 per unit on the National Stock Exchange (NSE) at 9:33 am.

"We would like to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, January 02, 2026, inter alia, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the second quarter and half year ended on September 30, 2025 and to consider the other business(es)," the company had said in an exchange filing.

The scrip had debuted at ₹1,470 per share on the National Stock Exchange (NSE), a premium of 38.42% over the IPO issue price of ₹1,062.

The ₹655.68 crore initial public offer was exclusively an offer for sale (OFS) of 0.62 crore shares by promoters Dr Kirtikumar Laxmidas Mehta, Dipabahen Niravkumar Mehta, Brinda Ankur Mehta, Minaxi Kirtikumar Mehta, and existing investors Sepia Investments, Anchor Partners and Sage Investment Trust.

The IPO was subscribed 137.04 times, with bids for 62,65,41,440 shares compared to 45,71,882 equity shares on offer, according to the NSE data.

Prior to the IPO, the firm had raised ₹195 crore from anchor investors, including SBI Mutual Fund (MF), HDFC MF, Axis MF, ICICI Prudential MF, Invesco MF, Kotak MF, DSP MF and SBI Life Insurance Company, among others.

Ahmedabad-headquartered Corona Remedies is a pharmaceutical formulation firm, which develops, manufactures and markets products in women's healthcare, cardio-diabetology, urology, pain management and other therapeutic areas.